Verismo Therapeutics Expands KIR-CAR Platform with In Vivo CAR T Technology from Stanford
Verismo Therapeutics Enhances KIR-CAR Technology
Verismo Therapeutics, a leading clinical-stage company focused on CAR T cell therapy, has recently announced a strategic licensing agreement with Stanford Medicine. This collaboration aims to innovate its multi-chain KIR-CAR platform by incorporating the advanced PACK-IT technology developed in the lab of Dr. Crystal Mackall. Through this initiative, Verismo is poised to transform the development of in vivo oncology candidates, a meaningful step towards creating "off-the-shelf" therapies that promise quicker delivery and cost-effectiveness for cancer treatment.
The KIR-CAR Platform: A Breakthrough in Cancer Therapy
At the heart of Verismo's offerings is the multi-chain KIR-CAR platform, which diverges from the traditional single-chain CAR T therapies. By employing a structure drawn from natural killer (NK) cells, this technology aims to generate robust and sustained anti-tumor activity without causing T cell exhaustion - a common issue with existing therapies. Verismo's current clinical candidates, SynKIR™-110 and SynKIR™-310, are under evaluation in Phase 1 trials targeting solid tumors and blood-related malignancies. The promising results from these trials were highlighted at the American Association for Cancer Research (AACR) 2026 Annual Meeting, showcasing their potential efficacy and safety profiles.
Innovations Brought by PACK-IT Technology
The licensed PACK-IT platform serves as a pivotal enhancement for Verismo’s KIR-CAR technology. Unlike traditional approaches that rely on a time-consuming and complex ex vivo process — where a patient's cells are collected, modified, and expanded in a laboratory — PACK-IT utilizes lentiviral particles to directly convey CAR genes into T cells. This method can be utilized both within the body (in vivo) or in an accelerated ex vivo manner, significantly shortening preparation time.
By focusing on an in vivo configuration, Verismo aims to compress the lengthy weeks spent in manufacturing into a swift and efficient same-day process. This is expected to lower costs and improve patient accessibility to groundbreaking therapies.
Current Clinical Developments
Verismo Therapeutics is actively progressing in two significant Phase 1 clinical trials:
1. SynKIR™-110 (NCT05568680): This candidate targets solid tumors and has demonstrated a promising safety profile and dose-dependent efficacy.
2. SynKIR™-310 (NCT06544265): Focused on B-cell malignancies, it has shown early signs of complete response even at the lowest dose levels.
Both trials underline Verismo's commitment to advancing CAR T therapies and tackling the challenges posed by traditional treatments.
Looking Ahead
Bryan Kim, CEO and Co-Founder of Verismo Therapeutics, emphasized that their KIR-CAR platform is central to the company’s mission of revolutionizing cancer treatment. The addition of the PACK-IT technology allows for real strides in realizing the full potential of CAR T therapies, ultimately aiming to deliver effective treatments to more patients at a reduced cost. This aligns with Verismo's vision to address critical unmet medical needs, especially in the challenging domains of solid tumors and B cell-related disorders.
Verismo Therapeutics continues to lead the charge in CAR T cell therapy innovation, promising a brighter future for patients grappling with complex cancer challenges. As they forge ahead, the collaboration with Stanford Medicine represents a significant step in bridging advanced research with real-world clinical applications, furthering the mission of accessible and effective cancer treatments for all.